India, March 19 -- The move marks a significant step in scaling LMS's peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO operations, supported by dedicated peptide manufacturing capacity across two additional specialized units. These improvements will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions.

Dr. Abdelaziz Toumi, chief executive officer, Lupin Manufacturing Solutions, said, "As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores o...